Epigenetics and Metabolism in Health and Disease by Tzika, Evangelia et al.
fgene-09-00361 September 12, 2018 Time: 19:6 # 1
MINI REVIEW
published: 18 September 2018
doi: 10.3389/fgene.2018.00361
Edited by:
Jane Mellor,
University of Oxford, United Kingdom
Reviewed by:
Lori A. Pile,
Wayne State University, United States
Ian C. G. Weaver,
Dalhousie University, Canada
*Correspondence:
Evangelia Tzika
evangelia.tzika@4sc.com
Axel Imhof
imhof@lmu.de;
axelimhof@me.com
Specialty section:
This article was submitted to
Epigenomics and Epigenetics,
a section of the journal
Frontiers in Genetics
Received: 28 June 2018
Accepted: 21 August 2018
Published: 18 September 2018
Citation:
Tzika E, Dreker T and Imhof A (2018)
Epigenetics and Metabolism in Health
and Disease. Front. Genet. 9:361.
doi: 10.3389/fgene.2018.00361
Epigenetics and Metabolism in
Health and Disease
Evangelia Tzika1,2* , Tobias Dreker1 and Axel Imhof2,3*
1 4SC AG, Translational Pharmacology, Munich, Germany, 2 Faculty of Medicine, Ludwig Maximilians University of Munich,
Munich, Germany, 3 Protein Analysis Unit (ZfP), Biomedical Center, Ludwig Maximilians University of Munich, Munich,
Germany
In the next 10 years, one billion people are estimated to suffer from
disabling consequences of metabolic disorders, making them the number one
noncommunicable disease on a global scale by 2030. Lots of risk factors such as
dietary intake, lack of exercise and other life style behaviors are considered to play
a role in the development of metabolic disorders. Despite the efforts that have been
undertaken to unravel their potential causes, the underlying molecular mechanisms
remain elusive. Evidence suggests that the pathogenesis involves changes on chromatin
and chromatin-modifying enzymes, which can contribute to a persistent dysregulated
metabolic phenotype. Indeed, a rising number of studies links epigenetic alterations with
the diagnosis and prognosis of metabolic disorders. A prerequisite for exploiting these
findings for pharmacological intervention is a detailed understanding of how differential
epigenetic modifications control cell metabolism. In this mini review, we summarize
the recent advances in uncovering the interplay between epigenetics and metabolic
pathways on a cellular level and highlight potential new avenues for alternative treatment
strategies.
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INTRODUCTION
Noncommunicable diseases (NCDs) are the leading cause of morbidity and mortality worldwide
(WHO, 2017). Metabolic diseases constitute the greatest part of NCDs and according to the
International Diabetes Federation (IDF) atlas for 2017, more than 693 million people will be
suffering from diabetes by 2045 (IDF, 2017). Obesity and cardiovascular diseases are rising (WHO,
2014) with the prevalence of obesity projected to 1 billion people worldwide by 2030 (Kelly et al.,
2008). A group of risk factors such as high fasting blood sugar, high blood pressure, low HDL
cholesterol level and others are defined as the “metabolic syndrome,” which is thought to predict or
increase the risk for diabetes and heart diseases (NIH, 2016). These data emphasize the urgent
need to find better prevention methods and therapies for the metabolic syndrome. However,
many questions remain unanswered about the pathology of the metabolic diseases and factors
such as life style behavior like nutrition habits and training routine are considered to play a role
in the development of the diseases across different patients (Jumpertz von Schwartzenberg and
Turnbaugh, 2015; Zeevi et al., 2015; Khera et al., 2016; Phillips, 2016). The molecular mechanisms
that frame the influence of metabolism on possible gene deregulation patterns, underpinning
causality and onset of metabolic diseases, are far from being fully understood. Epigenetics
and metabolism trade interacting factors dynamically and reciprocally, while constantly being
modulated by multifactorial external stimuli, unfolding correlations among different pathological
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conditions. In addition to immediate physiological effects like
hormonal dysregulation and generation of adipose tissue, life
style factors and food intake in particular may also affect the
epigenome. For instance, there is strong evidence that nutritional
habits can influence gene transcription epigenetically (van Dijk
et al., 2015; Etchegaray and Mostoslavsky, 2016) and there are
several studies claiming inheritance to the offspring (Figure 1)
(Seki et al., 2012; Nicholas et al., 2013; Rando and Simmons,
2015). A recent genome wide analysis of DNA methylation in
children born to parents affected by the Dutch famine showed
that 70 years later several DNA regions associated with growth
and metabolism were significantly differentially methylated,
including genes involved in control of birth weight and LDL
cholesterol in later life (Tobi et al., 2015).
Apart from the influence of dietary habits on epigenetic
regulation of metabolism there are more societal factors such
as sleep patterns, meal timing and work shifts that cause
circadian misalignment. Even one night of sleep deprivation
results in hypermethylation of various tissue specific clock
genes, leading to increased insulin resistance and impaired
glucose tolerance (Donga et al., 2010; Cedernaes et al.,
2015; Fontana and Partridge, 2015; Morris et al., 2016).
Furthermore, metabolites are the substrates used to form
chromatin modifications and hold fundamental role in the
activity of all biochemical pathways. It has been shown that
metabolites deriving from various food sources can serve
as substrates for transcription factors and histone modifying
enzymes that then affect chromatin compaction, leading to
more sequestered or exposed areas of the genome and to
down- or upregulation of gene transcription, respectively (Lu
and Thompson, 2012; Gut and Verdin, 2013; Fan et al.,
2015).
On the other hand, there are several lines of evidence
suggesting that epigenetics in turn could affect metabolism and
disease (Crunkhorn, 2011; Heerboth et al., 2014; Kwak and Park,
2016). Hence, current efforts to examine epigenetic targets as
future druggable candidates for metabolic diseases should be
further increased. In this review, we will therefore focus on
the complex and bidirectional interplay between epigenetics and
metabolism and how this connection can be dysregulated in
human disease.
RARE DISEASES: HOW MUTATIONS IN
GENES OF EPIGENETIC REGULATORS
ARE ASSOCIATED WITH METABOLIC
PHENOTYPES AND DEVELOPMENTAL
TRANSGENERATIONAL DISEASES
Rare diseases are a group of human diseases defined by a very
small amount of people affected by them. The vast majority
of rare diseases still lack any therapy partially due to our very
limited understanding of their pathomechanisms but also due
to the lack of identified druggable targets. They encompass
monogenetic as well as complex disorders, although not all rare
diseases have a genetic background. Symptoms can vastly vary
from birth dysplasia over to gradual atrophy and in multiple cases
development of metabolic phenotypes.
Rett syndrome (RTT; OMIM 312750) is a rare progressive
neurodegenerative disease affecting girls, characterized by
reduced brain volume, speech and motor disabilities, breathing
irregularities muscle deterioration throughout patient’s life and
many metabolic complications. It is mainly caused by any
of various mutations in one gene, coding for methyl-CpG-
binding protein 2 (MECP2) (Kyle et al., 2016). MECP2’s
central role is to regulate epigenetic imprinting and chromatin
compaction. By selectively binding to methylated DNA, MECP2
regulates gene transcription through association with chromatin-
remodeling complexes, including type I histone deacetylases
(HDACs) (Justice et al., 2013). However, MECP2 influences
many different biological pathways on multiple levels and the
molecular pathways from gene to phenotype are currently not
fully understood (Justice et al., 2013). Several studies though
have begun to shed light on the mechanism behind RTT’s
metabolic symptoms. In one study lipid metabolism was widely
affected in MECP2 null mice, both in the brain and systemically
(Buchovecky et al., 2013). Furthermore, abnormal mitochondrial
function and morphology has been described in RTT patients and
MECP2 mouse models (Kriaucionis et al., 2006). In recent studies
MECP2 was found to regulate lipid homeostasis by recruiting the
repressor complex, NCoR1/SMRT - HDAC3, to its lipogenesis
targets in hepatocytes. Also, Mecp2 mutant mice develop fatty
liver disease and dyslipidemia similar to HDAC3 liver-specific
deletion (Kyle et al., 2016). These findings position MECP2 as an
epigenetic component and regulator of metabolic homeostasis.
RTT is not the only rare disease with a direct link between
epigenetics and metabolism. However, mutations in many of
various epigenetic regulatory enzymes have historically first been
associated with cancer. It has become clear that cell metabolism
and cancer are tightly linked. For this reason, it is not surprising
that many cancer-associated genes can also cause metabolic
disease phenotypes without cancer symptoms. In particular,
histone-lysine N-methyltransferase 2D (KMT2D), also known as
MLL4 or MLL2 in humans and Mll4 or Mll2 in mice, is a major
histone H3 lysine 4 (H3K4) mono-methyltransferase (Lee et al.,
2013). It is primarily linked with acute myeloid leukemia, lung
and colon cancer (Rao and Dou, 2015). However, mutations in
KMT2D are also associated with Kabuki syndrome, which is a
multiple congenital anomaly syndrome characterized by facial
and skeletal anomalies, mild to moderate intellectual disability
and postnatal growth deficiency (Van Laarhoven et al., 2015).
In about 45–80% of patients’ mutations in the KMT2D gene
are detected. While muscoskeletal abnormalities are the primary
presentations of Kabuki syndrome, patients also suffer from
metabolic deregulation symptoms later in life. Apart from the
Kabuki syndrome, KMT2D has been shown to play a role in
the development of congenital heart disease (Zaidi et al., 2013).
Although the precise molecular mechanism underlying KMT2D’s
impact on metabolism remains to be uncovered and might differ
from disease to disease, it has been shown before that mutations
in Mll2 result in insulin resistance and impaired glucose tolerance
in mice (Goldsworthy et al., 2013). Furthermore, KMT2D mutant
mice revealed features of mild non-alcoholic fatty liver disease
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FIGURE 1 | Environmental factors affect epigenetics and metabolism and control disease predisposition in later life stages.
(NAFLD), elevated cholesterol and triglycerides plasma levels.
Another study identified KMT2D and KMT2C as regulators of
the hepatic circadian clock and co-activators of the circadian
transcription factors retinoid-related orphan receptor (ROR)-α
and -γ, which have been implicated before in controlling lipid
metabolism (Lau et al., 2008; Kim et al., 2015). In mice, KMT2D
also acts as a coactivator of PPARγ within the liver to direct
over-nutrition induced steatosis. Heterozygous Kmt2d+/−mice
exhibit resistance to over-nutrition induced hepatic steatosis
(Kim et al., 2016).
DNA methylation in mammals has long been implicated
in the epigenetic mechanism of parental imprinting, in which
selective expression of one allele of specific genes is governed
by parental origin. To date, all imprinting control regions
(ICRs) identified are differentially DNA methylated regions
(DMRs) on the two parental chromosomes and are heritably
maintained in the developing embryo. However, the role of
histone modifications is less clear. DMRs are characterized by
the asymmetrical accumulation of different histone modifications
on the two parental chromosomes and a requirement for histone
demethylation in order to establish germline DNA methylation
has been identified at some ICRs (Ciccone et al., 2009).
Imprinting disorders are a group of 12 diseases with overlapping
clinical characteristics and common epigenetic patterns. They
have been shown to affect growth, development and metabolism
(Livingstone and Borai, 2014). In patients with Silver–Russell
syndrome (SRS) the most common underlying disease-associated
epigenetic change is loss of methylation on chromosome 11p15
(Schönherr et al., 2006). However, the molecular etiology remains
unknown in a substantial cohort of patients. CpG islands
represent the most interesting genomic regions for examining
differences in methylation in SRS because methylation changes in
these regions directly influence the local epigenetic environment
to regulate gene expression. Interestingly, a recent study showed
that CpG islands which are differentially methylated in SRS were
enriched for genes linked to metabolism (Prickett et al., 2015).
This could be a potential link between the observed metabolic
symptoms of SRS patients, which include obesity, cardiovascular
disorders and type II diabetes (Wakeling et al., 2017).
A number of imprinted genes contribute to the control of
energy homeostasis and glucose regulated metabolism, including
IGF2 and GRB10, DLK1 (Livingstone and Borai, 2014). Diseases
associated with these genes serve to underline their importance
for normal metabolic regulation, as exemplified by Beckwith–
Wiedemann syndrome (BWS). BWS is an inherited condition
characterized by excessive IGF2 expression, usually resulting
from loss of imprinting. Hypoglycemia occurs in 50% of cases
of BWS. This is caused by hyperinsulinism, rather than being a
direct effect of Igf2, but the underlying β-cell defect is unknown
(Sparago et al., 2004; Adachi et al., 2013). Epigenetic studies have
shown that parental obesity can affect methylation of IGF2 of the
fetus correlating these changes with birth weight and metabolic
syndrome later in life (Hoyo et al., 2012; Soubry et al., 2013). In
animal models, parental caloric restriction influences epigenetic
regulation of Igf2 (Zhang et al., 2011). Transmission of a null
Grb10 allele results in reduced adiposity, increased lean mass and
improved glucose tolerance potentially via the Igf1 signaling and
controlled insulin production (Mokbel et al., 2014). Interestingly,
hypomethylation of the GRB10 locus has been implicated in the
development of both SRS and Beckwith–Wiedemann syndromes
(Scott and Moore, 2012; Koren and Palladino, 2016). Another
potential factor governing a transgenerational epigenetic disease
risk is DLK1 (also known as preadiposite factor 1) (Andersen
et al., 2009). It is expressed in high level in preadipocytes, and
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downregulation of Dlk1 correlates with adipocyte differentiation
in vitro. In an animal model a regulatory mutation causing
partial loss of imprinting of the Dlk1-Dio3 cluster caused
embryonic hypothyroidism in the offspring (Charalambous and
Hernandez, 2013). The animals exhibit postnatal hypothyroidism
and impaired brown tissue development due to overexpression
of Dlk1, leading to lifelong hypothyroidism, obesity and glucose
intolerance.
Taken together, it is becoming clear that DNA methylation,
imprinting and chromatin modifications play crucial roles in the
regulation of metabolism, and that their dysregulation in disease
can cause devastating outcomes. Similarly, these epigenetic
drivers of metabolism can be influenced by various non-genetic
and extracellular cues, thereby mediating transgenerational
effects on metabolism.
CANCER: EPIGENETIC AND METABOLIC
INTERACTIONS
Dysregulated metabolism is a hallmark of cancer (DeBerardinis
and Chandel, 2016; Vander Heiden and DeBerardinis, 2017).
Warbung was the first to describe an increased consumption
of glucose by tumor tissues in comparison to normal cells
(Warburg et al., 1927). High glutamine demand is another tumor
characteristic, since glutamine is a key nitrogen input for the
biosynthesis of cell components required for the fast growth
typical of cancerous tissues (Eagle, 1955; Nicklin et al., 2009;
DeBerardinis and Cheng, 2010). Due to their central role in cells,
metabolic pathways are strictly regulated – and not just by the
direct energy requirements of the cell. It has been demonstrated
that the influx of glucose into cells is not only driven by the
immediate bioenergetic needs of a cell but is also modified by
extracellular stimuli (Grassian et al., 2011). Interestingly, tumor
tissue might rely on nutrient adaptation and cell interactions in its
microenvironment to obtain fast cell growth and proliferation. In
line with this, it has been shown that in cancer, several metabolic
pathways are dysregulated and are reprogrammed to favor tumor
development even in the absence of essential nutrients (Boroughs
and DeBerardinis, 2015).
Furthermore, the origin and the etiology of the tumor,
the local nutrient availability and potency of metastasis, could
excite activation of different metabolic pathways (Boroughs and
DeBerardinis, 2015). Therefore, in the past years tumors started
being profiled depending on their metabolic regulation (Yuneva
et al., 2012; Wang et al., 2016). One caveat of metabolic tumor
classification is that different areas of the same tumor show high
metabolic heterogeneity, as shown by various screens setting out
to identify metabolic changes for tumor categorization (Denkert
et al., 2006; Li and Deng, 2017; Russell et al., 2017).
Despite the genetic and histological heterogeneity, tumor
development seems to involve the common induction of a
defined group of pathways to support core functions like
anabolism, catabolism, and redox balance (Cantor and Sabatini,
2012). The rewired metabolism of cancer cells could be a cause or
a consequence of the multiple changes in the epigenome which
is tightly linked with nutrient and metabolite availability. Indeed,
several studies have demonstrated that metabolic changes affect
the epigenome to promote more cancerogenic alterations (Cai
et al., 2011; Fan et al., 2015; Pietrocola et al., 2015; Feinberg
et al., 2016; Roe et al., 2017). Furthermore, the epigenome may
act in favor of uncoupling normal metabolic functions in favor of
tumorigenic development.
A long list of metabolites play key roles as signaling molecules
in the regulation of epigenetics in normal cells, including
S-adenosyl methionine (SAM), which is required by DNA
methyltransferases (DNMTs) and histone methyltransferases
(HMTs) (Rea et al., 2000), flavin adenine dinucleotide (FAD)
and 2-oxoglutarate (2-OG), which regulate lysine demethylases
(KDM), acetyl-CoA, which is required for the addition of
acetyl groups to histones by histone acetyl transferases (HATs)
and nicotinamide adenine dinucleotide (NAD) which serves
as a cofactor for class III histone deacetylases (Galdieri and
Vancura, 2012). Metabolites therefore are involved in regulating
all essential steps in establishing, modulating and removing
epigenetic marks on histones.
Dysregulation of the cellular levels of these metabolites
therefore establish direct routes of affecting the epigenome and
subsequently impact cancer development (Kaelin et al., 2013;
Mehrmohamadi et al., 2016). Mutations in the metabolic enzyme
isocitrate dehydrogenase 1(IDH1) and IDH2 have been linked
with glioblastoma and acute myeloid leukemia (Losman and
Kaelin, 2013). These mutations cause altered enzymatic activity
resulting in the production of the R-2-hydroxyglutarate (R-2HG)
metabolite. High levels of R-2HG interfere with the function of
dioxygenases requiring 2-oxoglutarate (2-OG) as a co-substrate.
Dioxygenases play crucial roles in cells and include prolyl
hydroxylases, cytosine hydroxylases, and histone demethylases.
Inhibition of the TET DNA- and JmjC histone-demethylase
families by increased levels of R-2HG influence gene expression
in part via an altered epigenetic state, characterized by a failure
to express differentiation programs (Dang et al., 2009; Figueroa
et al., 2010). In this case even though the production of R-2HG
is linked with metabolic deregulation, its effect on cancer fate
seems to be of a non-metabolic nature, by causing a lack of
differentiation.
Mutations in genes encoding fumarate hydratase (FH) and
succinate dehydrogenase (SDH) have also been identified in
many cancers. These mutations result in excess amounts of
their products, which are both TCA cycle intermediates (Xiao
et al., 2012). Even though they reprogram TCA cycle metabolism,
similar to the IDH1/IDH2 mutations, the involvement of
fumarate and succinate in cancer progression might be linked
with extensive alterations in the epigenome as they also affect
dioxygenase activity (Kaelin et al., 2013; Laukka et al., 2016).
Though mutations in genes related to cancer growth signaling
pathways are at the moment outnumbering identified alterations
in metabolic enzymes, increasing evidence demonstrates the
importance of metabolic pathways in driving and supporting
tumorigenesis. In particular, transcriptional factors, which are
key players in androgen response, hypoxia, glycolysis, and
lipid metabolism pathways, act synergistically with KDM3A to
promote cancer (Wilson et al., 2016, 2017). Furthermore, in a
study of 58 cancer cell types, DNA enhancer methylation was a
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strong predictor of cancer related gene expression and two thirds
of the affected (hypomethylated/upregulated) genes had function
in metabolic processes (Van Damme et al., 2016).
INTERVENTIONS AND FUTURE
ASPECTS
As of June 2018, there were nine FDA-approved drugs that act
primarily by targeting epigenetic mechanisms. Although most
of these early drugs were approved for cancer treatment, an
expanding portfolio of molecules targeting epigenetic factors in
other diseases now is in preclinical and clinical development
(Qi et al., 2016; Meighan-Mantha, 2017). Valproic acid is an
HDAC inhibitor for psychiatric disorders which recently is
being examined in clinical trials for different types of cancer.
Although clinical trials for DNMTis and HDACis were first
initiated 30 years ago, only in the past 5 years 2nd generation
epigenetic drugs have entered in clinical trials stage. These
novel drugs show higher potency and specificity targeting other
enzymes, including bromodomain and extra terminal protein
(BET), lysine-specific demethylase 1A (LSD1/KDM1A), mutant
isocitrate dehydrogenase (IDH), histone methyltransferase
(HMT) and protein arginine methyltransferase (PRMT). A recent
but promising trend in the cancer treatment landscape is
combination therapies of epigenetic drugs with other compounds
(Dueñas-Gonzalez et al., 2014; Ahuja et al., 2016; Raynal
et al., 2017). Epigenetic inhibitors could be the lead to treat
multiple disease types apart from cancer. For example, ESR1
and ESR2, which are expressed in smooth vascular muscle
cells, are usually hypomethylated in human atherosclerosis and
folic acid deprivation is shown to play a role in endothelial
dysfunction linked with cardiovascular disease and aging (Kim
et al., 2007; Kok et al., 2015). As far as various neurological
disorders are concerned, epigenetic modifications have long
been implicated in the nervous system’s aging, plasticity and
memory (Jakovcevski and Akbarian, 2012). ORY-2001 is the
first Alzheimer’s related epigenetic drug that entered clinical
phase I last year (Maes et al., 2016; Meighan-Mantha, 2017).
Huntington’s (HD) is another neurodegenerative disease caused
by a polyglutamine repeat sequence in the huntingtin protein,
which inhibits HATs leading to a decrease of H3 and H4 histone
acetylation. There are few recent studies showing that HDACi
treatment halts effects of HD in vivo as well as other molecules
that are still under investigation (Gray, 2010; Bürli et al., 2013;
Duan, 2013). Other HDACi have also recently been used for
the treatment of diabetes (Mau and Yung, 2014). However,
it still remains elusive how epigenetic inhibitors affect the
underlying disease-causing mechanisms. Novel ideas have arisen
such as investigating metabolic checkpoint inhibitors for cancer
treatment and reversal of progression (Scharping and Delgoffe,
2016). There are reasons to be optimistic that in the next years
we will be able to better control the bidirectional relationship
between epigenetic switches and metabolism and thereby address
disease progression. Epigenetic interventions could improve
the health state of people in reproductive age and halt disease
development or transgenerational inheritance of the metabolic
syndrome, which is critical to relief societal health burden.
New epigenetics-based diagnostic tests may also help classify
individuals with chronic diseases, prescribe pharmaceutical
treatments fitting to the patient’s profile, minimize possible
cytotoxicity or adjust dietary needs for health improvement of
the individual. Furthermore, metabolic changes can be detected
as early signs of various diseases including neurodegeneration
(Kennedy et al., 2016).
CONCLUSION
A growing body of evidence supports the intimate crosstalk
between metabolism and epigenetics. Pathogenic conditions
in which the interplay between metabolism and epigenetics
is dysregulated, range from the rarest to the most common
noncommunicable diseases of humanity. This bidirectional
relationship could serve as the substratum of more complex
organismal interrelations and intrarelations. It is therefore crucial
that more fine-tuned research needs to be performed toward
unraveling novel epigenetic players that regulate metabolism, and
vice versa. Pinpointing the molecular mechanisms involved in
key epigenetic enzyme regulation will support novel therapeutic
approaches for various metabolic disorders. Furthermore,
findings regarding epigenetic regulation of metabolism will reveal
the untapped potential to modify pathological disease states.
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